NOTICE: April 2018 was the final issue of this publication.
The authors of a recent study concluded that among hip or knee arthroplasty patients who receive five days of postoperative rivaroxaban, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism.
Researchers have determined that edoxaban was noninferior to dalteparin regarding the composite outcome of recurrent VTE or major bleeding, although recurrent VTE was lower and bleeding was higher with edoxaban.
What About Aspirin for PCI Patients?
Should clinicians continue using aspirin for patients with prior percutaneous coronary intervention who are undergoing noncardiac surgery? The answer appears to be yes based on the results of a new study from Canada.
This year’s flu vaccine was only 36% effective, according to the CDC.
In this section: The agency approves a new drug for prostate cancer and expands the indication for a non-small cell lung cancer treatment.
Financial Disclosure: To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, Dr. Elliott, Ms. Coplin, Mr. Springston, and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.